Dopamine d2 receptor relies upon ppm/pp2c protein phosphatases to dephosphorylate huntingtin protein

Journal of Biological Chemistry

Volumn 289, Issue 17, 2014, Pages 11715-11724

  Marion, Sébastien ^a   Urs, Nikhil M ^a   Peterson, Sean M ^a   Sotnikova, Tatyana D ^d   Beaulieu, Jean Martin ^e   Gainetdinov, Raul R ^d   Caron, Marc G ^a,b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITÉ LAVAL   (Canada)

^e ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPHYSIOLOGY; PHOSPHATASES; PROTEINS;

DEPHOSPHORYLATIONS; HUNTINGTIN; MOTOR FUNCTION; PHARMACOLOGICAL INHIBITION; PROTEIN PHOSPHATASE; RECEPTOR ACTIVATION; SIGNALING PATHWAYS; THERAPEUTIC POTENTIALS;

AMINES;

BETA ARRESTIN 2; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HUNTINGTIN; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 1A; PHOSPHOPROTEIN PHOSPHATASE 1B; PHOSPHOPROTEIN PHOSPHATASE 2; PHOSPHOPROTEIN PHOSPHATASE 2C; PROTEIN KINASE B; SERINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

AKT; ARRESTIN; DOPAMINE D2 RECEPTOR; DOPAMINE RECEPTORS; G PROTEIN-COUPLED RECEPTORS (GPCR); G PROTEINS; HUNTINGTIN; PHOSPHATASE; PP2C;

ANIMALS; HEK293 CELLS; HUMANS; MICE; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DOPAMINE D2;

EID: 84899439613     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.544312     Document Type: Article

References (41)

1. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993
2. Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., and Caron M. G. (2006) Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J. 20, 2541-2543
3. Cyr, M., Beaulieu, J.-M., Laakso, A., Sotnikova, T. D., Yao, W.-D., Bohn, L. M., Gainetdinov, R. R. and. Caron, M. G. (2003) Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U.S.A. 100, 11035-11040
4. Charvin, D., Vanhoutte, P., Pagès, C., Borrelli, E., and Caboche, J. (2005) Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl. Acad. Sci. U.S.A. 102, 12218-12223
5. Charvin, D., Roze, E., Perrin, V., Deyts, C., Betuing, S., Pagès, C., Régulier, E., Luthi-Carter, R., Brouillet, E., Déglon, N., and Caboche, J. (2008) Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol. Dis. 29, 22-29
6. Jankovic, J., and Beach, J. (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48, 358-362
7. Zheng, G., Dwoskin, L. P., and Crooks, P. A. (2006) Vesicular monoamine transporter 2: role as a novel target for drug development. AAPS J. 8, E682-E692
8. Huntington Study Group (2006) Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366-372
9. Luo, S., Vacher, C., Davies, J. E., and Rubinsztein, D. C. (2005) Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity. J. Cell Biol. 169, 647-656
10. Aiken, C. T., Steffan, J. S., Guerrero, C. M., Khashwji, H., Lukacsovich, T., Simmons, D., Purcell, J. M., Menhaji, K., Zhu, Y.-Z., Green, K., Laferla, F., Huang, L., Thompson, L. M., and Marsh, J. L. (2009) Phosphorylation of threonine 3: implications for Huntingtin aggregation and neurotoxicity. J. Biol. Chem. 284, 29427-29436
11. Gu, X., Greiner, E. R., Mishra, R., Kodali, R., Osmand, A., Finkbeiner, S., Steffan, J. S., Thompson, L. M., Wetzel, R., and Yang, X. W. (2009) Serines 13 and 16 are critical determinants of full-length human mutant hunting- tin induced disease pathogenesis in HD mice. Neuron 64, 828-840
12. Atwal, R. S., Desmond, C. R., Caron, N., Maiuri, T., Xia, J., Sipione, S., and Truant, R. (2011) Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat. Chem. Biol. 7, 453-460
13. Havel, L. S., Wang, C.-E., Wade, B., Huang, B., Li, S., and Li, X.-J. (2011) Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. Hum. Mol. Genet. 20, 1424-1437
14. Sacco, F., Perfetto, L., Castagnoli, L., and Cesareni G (2012) The human phosphatase interactome: An intricate family portrait. FEBS Lett. 586, 2732-2739
15. Colin, E., Zala, D., Liot, G., Rangone, H., Borrell-Pagès, M., Li, X. J., Saudou, F., and Humbert, S. (2008) Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons.EMBO J. 27, 2124-2134
16. Humbert, S., Bryson, E. A., Cordelières, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., Greenberg, M. E., Saudou, F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831-837
17. Warby, S. C., Chan, E. Y., Metzler, M., Gan, L., Singaraja, R. R., Crocker, S. F., Robertson, H. A., and Hayden, M. R. (2005) Huntingtin phosphorylation on serine 421 is significantly reduced in the striatum and by polyglutamine expansion in vivo. Hum. Mol. Genet. 14, 1569-1577
18. Pardo, R., Colin, E., Régulier, E., Aebischer, P., Déglon, N., Humbert, S., and Saudou, F. (2006) Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J. Neurosci. 26, 1635-1645
19. Beaulieu, J. M., Sotnikova, T. D., Marion, S., Lefkowitz, R. J., Gainetdinov, R. R., and Caron, M. G. (2005) An Akt/α-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273
20. Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., and Lin, F. T. (1999) Enhanced morphine analgesia in mice lacking α-arrestin 2. Science 286, 2495-2498
21. Metzler, M., Gan, L., Mazarei, G., Graham, R. K., Liu, L., Bissada, N., Lu, G., Leavitt, B. R., and Hayden, M. R. (2010) Phosphorylation of Huntingtin at S421 in YAC128 Neurons Is Associated with Protection of YAC128 Neurons from NMDA-Mediated Excitotoxicity and Is Modulated by PP1 and PP2A. J. Neurosci. 30, 14318-14329
22. Bialojan, C., and Takai, A. (1988) Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Biochem. J. 256, 283-290
23. Brewis, N. D., Street, A. J., Prescott, A. R., and Cohen P. T. (1993) PPX, a novel protein serine/threonine phosphatase localized to centrosomes. EMBO J. 12, 987-996
24. Chen, M. X., McPartlin, A. E., Brown, L., Chen, Y. H., Barker, H. M., and Cohen, P. T. (1994)Anovel human protein serine/threonine phosphatase, which possesses four tetratricopeptide repeat motifs and localizes to the nucleus. EMBO J. 13, 4278-4290
25. Weiser, D. C., and Shenolikar, S. (2003) Use of protein phosphatase inhibitors. in Current Protocols in Protein Science, Chapter 13, Unit 13.10, John Wiley & Sons, Inc., Hoboken, NJ
26. Cohen, P., and Cohen, P. T. (1989) Protein phosphatases come of age. J. Biol. Chem. 264, 21435-21438
27. Huang, X., and Honkanen, R. E. (1998) Molecular cloning, expression, and characterization of a novel human serine/threonine protein phosphatase, PP7, that is homologous to Drosophila retinal degeneration C gene product (rdgC). J. Biol. Chem. 273, 1462-1468
28. Jan, G., Delorme, V., David, V., Revenu, C., Rebollo, A., Cayla, X., and Tardieux, I. (2007) The toxofilin-actin-PP2C complex of Toxoplasma: identification of interacting domains. Biochem. J. 401, 711-719
29. Montini, E., Rugarli, E. I., Van de Vosse, E., Andolfi, G., Mariani, M., Puca, A. A., Consalez, G. G., den Dunnen, J. T., Ballabio, A., and Franco, B. (1997) A novel human serine-threonine phosphatase related to the Drosophila retinal degeneration C (rdgC) gene is selectively expressed in sensory neurons of neural crest origin. Hum. Mol. Genet. 6, 1137-1145
30. Rogers, J. P., Beuscher, A. E., 4th, Flajolet, M., McAvoy, T., Nairn, A. C., Olson, A. J., and Greengard, P. (2006) Discovery of protein phosphatase 2C inhibitors by virtual screening. J. Med. Chem. 49, 1658-1667
31. Hishiya, A., Ohnishi, M., Tamura, S., and Nakamura, F. (1999) Protein phosphatase 2C inactivates F-actin binding of human platelet moesin. J. Biol. Chem. 274, 26705-26712
32. Sun, W., Yu, Y., Dotti, G., Shen, T., Tan, X., Savoldo, B., Pass, A. K., Chu, M., Zhang, D., Lu, X., Fu, S., Lin, X., and Yang, J. (2009) PPM1A and PPM1B act as IKKß phosphatases to terminate TNFα-induced IKKα- NF-κB activation. Cell. Signal. 21, 95-102
33. Lan, H., Liu, Y., Bell, M. I., Gurevich, V. V., and Neve, K. A. (2009) A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding. Mol. Pharmacol. 75, 113-123
34. Shi, Y. (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139, 468-484
35. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V. C., Sharp, A. H., Persichetti, F., Cattaneo, E., and MacDonald, M. E. (2000) Dominant phenotypes produced by HD mutation in STHdhQ111 striatal cells. Hum. Mol. Genet. 9, 2799-2809
36. Pan, C., Liu, H.-D., Gong, Z., Yu, X., Hou, X.-B., Xie, D.-D., Zhu, X.-B., Li, H.-W., Tang, J.-Y., Xu, Y.-F., Yu, J.-Q., Zhang, L.-Y., Fang, H., Xiao, K.-H., Chen, Y.-G., Wang, J.-Y., Pang, Q., Chen, W., and Sun, J.-P. (2013) Cadmium is a potent inhibitor of PPM phosphatases and targets the M1 binding site. Sci. Rep. 3, 2333
37. Flajolet, M., Rakhilin, S., Wang, H., Starkova, N., Nuangchamnong, N., Nairn, A. C., and Greengard, P. (2003) Protein phosphatase 2C binds selectively to and dephosphorylates metabotropic glutamate receptor 3. Proc. Natl. Acad. Sci. U.S.A. 100, 16006-16011
38. Xiao, K., McClatchy, D. B., Shukla, A. K., Zhao, Y., Chen, M., Shenoy, S. K., Yates, J. R., 3rd, and Lefkowitz, R. J. (2007) Functional specialization of α-arrestin interactions revealed by proteomic analysis. Proc. Natl. Acad. Sci. U.S.A. 104, 12011-12016
39. Pineda, J. R., Pardo, R., Zala, D., Yu, H., Humbert, S., and Saudou, F. (2009) Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol. Brain 2, 33
40. Rosenstock, T. R., de Brito, O. M., Lombardi, V., Louros, S., Ribeiro, M., Almeida, S., Ferreira, I. L., Oliveira, C. R., and Rego, A. C. (2011) FK506 ameliorates cell death features in Huntington's disease striatal cell models. Neurochem. Int. 59, 600-609
41. Cho, D. I., Beom, S., Van Tol, H. H., Caron, M. G., and Kim, K. M. (2006) Characterization of the desensitization properties of five dopamine receptor subtypes and alternatively spliced variants of dopamine D2 and D4 receptors. Biochem. Biophys. Res. Commun. 350, 634-640